title: Phase II evaluation of mitozolomide in ovarian cancer.
authors.affiliation: Department of Medical Oncology, Gartnavel General Hospital, Glasgow, UK.
authors.forename: M
authors.initials: M
authors.lastname: Harding
authors.forename: D
authors.initials: D
authors.lastname: Northcott
authors.forename: J
authors.initials: J
authors.lastname: Smyth
authors.forename: N S
authors.initials: NS
authors.lastname: Stuart
authors.forename: J A
authors.initials: JA
authors.lastname: Green
authors.forename: E
authors.initials: E
authors.lastname: Newlands
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide